Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 07BANGKOK527, MORE COMPULSORY LICENSES LIKELY FOR THAILAND

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #07BANGKOK527.
Reference ID Created Released Classification Origin
07BANGKOK527 2007-01-25 23:48 2011-08-25 00:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Bangkok
VZCZCXRO8888
RR RUEHCHI RUEHDT RUEHHM RUEHNH
DE RUEHBK #0527/01 0252348
ZNR UUUUU ZZH
R 252348Z JAN 07
FM AMEMBASSY BANGKOK
TO RUEHC/SECSTATE WASHDC 4360
RUCNASE/ASEAN MEMBER COLLECTIVE
RUEHGV/USMISSION GENEVA 1766
RUEHNE/AMEMBASSY NEW DELHI 4337
RUCPDOC/USDOC WASHDC
RUEAHLC/HOMELAND SECURITY CENTER WASHDC
UNCLAS SECTION 01 OF 03 BANGKOK 000527 
 
SIPDIS 
 
SENSITIVE 
 
SIPDIS 
 
STATE PASS USTR FOR B. WEISEL, C. WILSON 
STATE PASS USPTO 
HHS/OHGA FOR AMAR BHAT, ERIKA ELVANDER 
USDOC FOR JKELLY 
 
E.O. 12958:N/A 
TAGS: ECON ETRD KIPR TH
SUBJECT:  MORE COMPULSORY LICENSES LIKELY FOR THAILAND 
 
REF:  SECSTATE 9256 
 
1.  (SBU) Summary:  The Minister of Public Health announced his 
intention to issue further compulsory licenses next week for 
HIV/AIDS medicines and heart medicine.  Similar to its earlier 
compulsory license on another HIV drug last November, the Ministry 
did not discuss or negotiate with patent holders before making the 
announcement.  Local industry is disturbed that the Ministry is 
considering licensing not only AIDS drugs but is moving toward 
breaking patents on other, more profitable therapeutic medicines and 
is considering changes in their investments in Thailand.  End 
Summary. 
 
2.  (SBU) On January 24, Minister of Public Health Mongkol na 
Songkhla announced to the press his Ministry's intention to issue 
compulsory licenses on three patented drugs, two for HIV treatment 
and another for heart disease.  The Minister withheld further 
details until an official announcement could be made on Monday, 
January 29.  The Minister's statement follows on the compulsory 
license announced last November for efavirenz, an HIV medicine 
patented by U.S.-based pharmaceutical company Merck & Co.  Although 
Mongkol did not identify the drugs to be licensed in this round, we 
understand they will be Kaletra, an antiretroviral produced by 
U.S.-based Abbott Labs, and one of its component drugs, probably 
ritonavir; and Plavix, a heart medicine produced jointly by French 
firm Sanofi-Aventis and U.S.-based Bristol Myers Squibb (but 
distributed by Sanofi Aventis in Thailand).  The RTG was also 
reportedly considering Pfizer's anti-cholesterol statin Lipitor, but 
is now looking into similar drugs that are already off patent as an 
alternative to breaking patents. 
 
3.  (SBU) The RTG intention to compulsory license Kaletra was 
unsurprising, health activists in and out of the government have 
long expressed a desire to find a cheaper version of this expensive 
second-line antiretroviral.  The RTG has committed to expand 
treatment to more HIV/AIDS patients and as a percentage of those 
patients inevitably develop resistance to first-line generic 
regimens, there will be both an increasing number and proportion of 
patients who require second-line drugs such as Kaletra.  Health 
officials have long expressed their fears that the commitment to 
treatment will stretch health budgets and possibly place at risk the 
financial situation of the entire universal health coverage system. 
 
4.  (SBU) Entry into other therapeutic medicines such as the heart 
medicine Plavix opens a new front.  Reportedly, an interagency 
committee on compulsory licenses met January 8 and developed a 
target list of drugs in four disease categories for potential future 
compulsory licenses.  In addition to cardiovascular drugs Lipitor 
and Plavix and the HIV drug Kaletra, the committee listed four 
cancer drugs and two antibiotics.  The committee recommended Kaletra 
and Plavix be next in line to be licensed, but it is unclear what 
timeline the others may follow. 
 
5.  (SBU) According to one member of the compulsory license 
committee, the Ministry of Public Health (MoPH) will follow a 
similar procedure to that done with efavirenz.  The Department of 
Disease Control will issue the license for Kaletra, while the 
Department of Medical Services will handle the process for Plavix. 
Both agencies have been instructed to send official letters of 
notification to the Department of Intellectual Property and to the 
patent holder once the compulsory license has been officially 
announced.  The committee does not believe cabinet approval is 
necessary for this round of compulsory licenses and it does not 
appear to have been discussed at that level. 
 
ACTIVIST OFFICIALS DRIVING MORE CL'S 
------------------------------------ 
 
6.  (SBU) The step to issue compulsory licenses is increasingly seen 
as a populist move by the military-installed government.  In a new 
government that is still feeling its way on how to govern, Mongkol 
is an activist Minister who has seen an opportunity to make a bold 
step forward in improving access to medicine with little opposition 
from other parts of the government.  A relatively small group of 
people is driving the compulsory licenses.  Dr. Sanguan 
Nitayaramphong, Secretary General of the National Health Security 
Office which manages the universal health care program and chairman 
of the interagency committee on compulsory licenses, apparently 
began the process of identifying which drugs to consider for 
compulsory licenses.  However, the main actor behind the process is 
considered to be Dr. Suwit Wibulpolprasert, Special Advisor on 
Health Economics at the MoPH.  Suwit had been an opponent of 
 
BANGKOK 00000527  002 OF 003 
 
 
pharmaceutical provisions in the proposed US-Thai FTA.  Dr. Suwit 
also this week spoke before a WHO Executive Board meeting in Geneva 
railing against pharmaceutical firms that use virus samples from 
Thailand to produce vaccines, but sell it back at unfair prices, 
saying "when the pandemic occurs, they survive and we die".  HHS is 
reportedly drafting a strong response. 
 
7.  (SBU) The expected spiraling financial outlays for HIV treatment 
and other medical care is an obvious motive for proceeding ahead 
with compulsory licenses, but less clear is why the MoPH has 
declined to negotiate or seriously discuss with pharmaceutical firms 
before issuing the licenses.  Dr. Sanguan and Dr. Suwit have each 
said privately and publicly that they had undertaken negotiations 
with the pharmaceutical firms and had made little progress, thus 
necessitating moving forward with the licenses.  The pharmaceutical 
firms, on the other hand, insist they never entered into any formal 
negotiations or discussions, though they have not publicly 
challenged the RTG on this point.  An executive VP of Sanofi-Aventis 
reportedly met with Minister Mongkol yesterday and offered to 
discuss prices on their antiplatelet agent Plavix, but asked that a 
CL not be issued as it would compromise their ability to negotiate 
later.  The Minister responded positively, but nevertheless notified 
the press only hours later that the license would go ahead (the 
Minister reportedly told Sanofi today he had not made the statement 
and that there had been a leak, but somehow most Bangkok papers 
sourced the information directly to him).  The local office of 
Abbott Labs has requested a meeting with the Minister as well, but 
the request was pushed down to the Department of Disease Control 
whom they will meet on Friday. 
 
8.  (SBU) The local industry pharmaceutical association, Prema, is 
reacting strongly to the move to issue licenses for not just 
HIV/AIDS drugs but other therapeutic medicines.  Prema issued a 
strongly worded press release today that expressed their alarm and 
suggested that a number of major firms will be reexamining their 
investment strategies in Thailand.  The statement aims to raise 
concerns over the already battered investment climate in Thailand. 
 
9.  (SBU) Ambassador Boyce lunched with PM Surayut on Wednesday and 
brought up the compulsory license issue, noting that consultation 
with affected firms was important for transparency.  Surayut 
appeared to be familiar with the issue and while not offering 
comment on it said he would bring it up with the Minister of Public 
Health.  The Ambassador also brought up the issue in his meeting 
today with Foreign Minister Nitya (reported septel). 
 
Update on individual CLs 
------------------------ 
 
10.  (SBU) Merck has heard that MoPH has ordered 66,000 bottles of a 
generic version of their drug efavirenz from Indian generic Ranbaxy, 
and that the first shipment should be arriving the second week of 
February.  The Government Pharmaceutical Organization (GPO) 
apparently was able to procure the generic for 700 baht per bottle 
(a one-month supply), approximately 180 baht less than Merck had 
been able to offer.  Thai FDA has approved the 200 mg version of 
generic efavirenz and will soon approve the more common 600 mg 
version.  Merck believes they are still in discussions with the RTG 
and may be able to present further price reductions. 
 
11.  (SBU) Abbott Labs has heard that the RTG is considering 
importing generic versions of its antiretroviral Kaletra from either 
Indian generic Cipla or Hetero.  Abbott does not believe that the 
WHO has qualified the generic from either company.  Abbott also 
expects to complete the registration process in March for a new 
heat-stable version of the drug which does not require 
refrigeration.  The new version has a reduced pill count (4 instead 
of 6 per day) and no dietary restrictions.  Abbott is uncertain 
whether a CL on Kaletra would cover its new version as well, but 
noted that no generic companies have yet to produce the new 
version. 
 
12.  (SBU) Comment:  Although we have been critical of the process 
the RTG has followed on issuing compulsory licenses, providing cheap 
antiretrovirals to poor AIDS patients is certainly a worthy goal. 
However, we and industry are concerned that a new front has opened 
and Thailand now seems to be moving to break patents on drugs simply 
because they are highly priced, and not necessarily for diseases 
that afflict the poor.  Embassy would appreciate any guidance on 
whether compulsory licenses on drugs not intended to treat pandemic 
diseases are treated differently under WTO TRIPS regulations.  We 
would also appreciate any guidance on whether points provided in 
 
BANGKOK 00000527  003 OF 003 
 
 
reftel have changed given today's new information. 
BOYCE